Company / Accounts Receivable
CASTLE BIOSCIENCES INC Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$43.4M
FY2025
5-year range
$17.3M / $51.2M
FY2021-FY2025
Trend
-15.3%
vs FY2024
Sector context
#115 of 137
Health Care
What the data says
CASTLE BIOSCIENCES INC's accounts receivable of $43M is lower than 84% of companies in the Health Care sector (FY2025). Accounts Receivable has fluctuated over the past 8 years, ranging from $12M in FY2018 to $51M in FY2024.
Based on SEC 10-K filings.
$43M in FY2025 with a 5-year CAGR of +27.7%.
Improved from $38M to $43M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +22.7%
- 5-Year CAGR
- +27.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 137This company $43.4M Sector average $1.3B
▼
-96.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.7%, indicating consistent growth.
- In FY2025, accounts receivable decreased 15.3% year-over-year.
- Ranks #115 out of 137 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.4M | -15.3% |
| FY2024 | $51.2M | +33.7% |
| FY2023 | $38.3M | +63.2% |
| FY2022 | $23.5M | +35.8% |
| FY2021 | $17.3M | +35.4% |
| FY2020 | $12.8M | -12.9% |
| FY2019 | $14.6M | +21.2% |
| FY2018 | $12.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026